JP2013505946A5 - - Google Patents

Download PDF

Info

Publication number
JP2013505946A5
JP2013505946A5 JP2012531043A JP2012531043A JP2013505946A5 JP 2013505946 A5 JP2013505946 A5 JP 2013505946A5 JP 2012531043 A JP2012531043 A JP 2012531043A JP 2012531043 A JP2012531043 A JP 2012531043A JP 2013505946 A5 JP2013505946 A5 JP 2013505946A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
moiety
cycloalkyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012531043A
Other languages
English (en)
Japanese (ja)
Other versions
JP5791611B2 (ja
JP2013505946A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/050079 external-priority patent/WO2011038162A1/en
Publication of JP2013505946A publication Critical patent/JP2013505946A/ja
Publication of JP2013505946A5 publication Critical patent/JP2013505946A5/ja
Application granted granted Critical
Publication of JP5791611B2 publication Critical patent/JP5791611B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012531043A 2009-09-23 2010-09-23 ピリド[3,4−b]インドールおよび使用方法 Expired - Fee Related JP5791611B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24514809P 2009-09-23 2009-09-23
US61/245,148 2009-09-23
PCT/US2010/050079 WO2011038162A1 (en) 2009-09-23 2010-09-23 Pyrido(3,4-b)indoles and methods of use

Publications (3)

Publication Number Publication Date
JP2013505946A JP2013505946A (ja) 2013-02-21
JP2013505946A5 true JP2013505946A5 (enExample) 2013-11-07
JP5791611B2 JP5791611B2 (ja) 2015-10-07

Family

ID=43796210

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012531043A Expired - Fee Related JP5791611B2 (ja) 2009-09-23 2010-09-23 ピリド[3,4−b]インドールおよび使用方法

Country Status (8)

Country Link
US (2) US20130137705A1 (enExample)
EP (1) EP2480079A4 (enExample)
JP (1) JP5791611B2 (enExample)
CN (1) CN102711467A (enExample)
AU (1) AU2010298167B2 (enExample)
BR (1) BR112012006644A2 (enExample)
CA (1) CA2775129A1 (enExample)
WO (1) WO2011038162A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
RU2544856C2 (ru) * 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CL2009000725A1 (es) 2008-03-24 2009-05-29 Medivation Technologies Inc Compuestos derivados de heterociclos con uniones puente sustituidos, moduladores de receptores adrenergicos, de serotonina, de dopamina y de histaminas; composicion farmaceutica; kit farmaceutico; y su uso en el tratamiento del trastorno cognitivo y trastorno psicotico.
WO2009120717A2 (en) 2008-03-24 2009-10-01 Medivation Technologies, Inc. Pyrido [3, 4-b] indoles and methods of use
CA2742320A1 (en) * 2008-10-31 2010-05-06 Medivation Technologies, Inc. Pyrido[4,3-b]indoles containing rigid moieties
CA2742322A1 (en) 2008-10-31 2010-05-06 Medivation Technologies, Inc. Azepino[4,5-b]indoles and methods of use
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
CN102405043B (zh) 2009-01-09 2017-08-22 得克萨斯州大学系统董事会 前神经原性化合物
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CN102480955B (zh) 2009-04-29 2015-08-05 梅迪维新技术公司 吡啶并[4,3-b]吲哚类和使用方法
CA2760516A1 (en) 2009-04-29 2011-02-17 Medivation Technologies, Inc. Pyrido[4,3-b]indoles and methods of use
WO2011038161A1 (en) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido[4,3-b]indoles and methods of use
US9079904B2 (en) 2009-09-23 2015-07-14 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use
EP2480081A4 (en) 2009-09-23 2013-03-06 Medivation Technologies Inc Bridged heterocyclic compounds and methods for their use
WO2011103460A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103485A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011103430A1 (en) 2010-02-19 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2012006419A2 (en) 2010-07-07 2012-01-12 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9434747B2 (en) 2011-02-18 2016-09-06 Medivation Technologies, Inc. Methods of treating diabetes
US8791132B2 (en) * 2011-02-18 2014-07-29 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
WO2012112964A2 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE
US9199985B2 (en) 2011-02-18 2015-12-01 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
WO2014031986A1 (en) 2012-08-24 2014-02-27 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
WO2015070234A2 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
CN104839184A (zh) * 2015-04-18 2015-08-19 广东中迅农科股份有限公司 含有氯吡嘧磺隆和氯氨吡啶酸以及烟嘧磺隆的农药组合物
US11458129B2 (en) 2017-11-02 2022-10-04 California Institute Of Technology Neurokinin antagonists and uses thereof
WO2019090000A1 (en) 2017-11-02 2019-05-09 California Institute Of Technology Expression of neuropeptides
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2642438A (en) * 1949-07-15 1953-06-16 Hoffmann La Roche Pyridindoles and method of manufacture
GB721171A (en) * 1951-04-30 1954-12-29 Bayer Ag Derivatives of ª‰- and ª†- carbolines
JPS3922979B1 (enExample) * 1962-04-10 1964-10-15
JPS3920857B1 (enExample) * 1962-05-17 1964-09-24
JPS412713B1 (enExample) * 1963-08-30 1966-02-21
US4754038A (en) * 1987-02-26 1988-06-28 American Home Products Corporation Carboline histamine H1 antagonists
ES2148347T3 (es) * 1993-09-09 2000-10-16 Scios Inc Antagonistas del receptor de la bradiquinina pseudo y no peptidica.
US5817756A (en) * 1993-09-09 1998-10-06 Scios Inc. Pseudo- and non-peptide bradykinin receptor antagonists
US5688807A (en) * 1994-03-11 1997-11-18 Eli Lilly And Company Method for treating 5HT2B receptor related conditions
CZ264996A3 (cs) * 1994-03-11 1998-01-14 Eli Lilly And Company Použití sloučenin, které jsou aktivní na 5HT2B receptor
AU5644296A (en) * 1995-05-05 1996-11-21 Novo Nordisk A/S Novel heterocyclic chemistry
GB9604996D0 (en) * 1996-03-08 1996-05-08 Black James Foundation Benzodiazonine derivatives
WO1999025340A1 (en) * 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease
FR2771095B1 (fr) * 1997-11-14 1999-12-17 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE69829317T2 (de) * 1997-12-25 2006-04-06 Meiji Seika Kaisha Ltd. Tetrahydrobenzindol-derivate
FR2796644B1 (fr) * 1999-07-23 2001-09-07 Adir Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
WO2004113336A1 (en) * 2003-06-16 2004-12-29 Chroma Therapeutics Limited Carboline and betacarboline derivatives for use as hdac enzyme inhibitors
EP1637521B1 (en) * 2003-06-23 2013-06-19 Ono Pharmaceutical Co., Ltd. Novel tricyclic heterocycle compound
JP4734119B2 (ja) * 2004-02-12 2011-07-27 田辺三菱製薬株式会社 インダゾール化合物及びその医薬用途
WO2006011750A1 (en) * 2004-07-27 2006-02-02 C & C Research Laboratories Tetrahydro-beta-carbolinone derivatives and process for preparing the same
US7772245B2 (en) * 2005-02-14 2010-08-10 Miikana Therapeutics, Inc. Inhibitors of histone deacetylase
MX2009008507A (es) * 2007-02-07 2009-08-20 Astellas Pharma Inc Derivado de acilguanidina.
DE102007009264A1 (de) * 2007-02-26 2008-08-28 Ellneuroxx Ltd. 9-Alkyl-ß-Carboline zur Behandlung von neurodegenerativen Erkrankungen
JP5580731B2 (ja) * 2007-04-05 2014-08-27 アンドレイ・アレクサンドロビッチ・イワシェンコ 置換された2,3,4,5−テトラヒドロ−1h−ピリド[4,3−b]インドール、その製造のための方法及び使用
RU2007139634A (ru) * 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
WO2009078423A1 (ja) * 2007-12-18 2009-06-25 National University Corporation University Of Toyama アルドース還元酵素阻害活性を有する縮合三環化合物
RU2544856C2 (ru) * 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2009120717A2 (en) * 2008-03-24 2009-10-01 Medivation Technologies, Inc. Pyrido [3, 4-b] indoles and methods of use
TW201038569A (en) * 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy

Similar Documents

Publication Publication Date Title
JP2013505946A5 (enExample)
JP2013505945A5 (enExample)
JP2011515483A5 (enExample)
JP2011515482A5 (enExample)
JP2013505947A5 (enExample)
JP2008200039A5 (enExample)
JP2018517746A5 (enExample)
JP2014051526A5 (enExample)
JP2012507567A5 (enExample)
JP2012528865A5 (enExample)
JP2018516243A5 (enExample)
JP2011500725A5 (enExample)
JP2016505586A5 (enExample)
JP2012532137A5 (enExample)
JP2018511628A5 (enExample)
JP2004534846A5 (enExample)
JP2015523339A5 (enExample)
JP2014521688A5 (enExample)
JP2013544846A5 (enExample)
JP2020504112A5 (enExample)
WO2010000372A3 (en) New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
JP2018504437A5 (enExample)
JP2018536648A5 (enExample)
JP2016513130A5 (enExample)
JP2017523169A5 (enExample)